NEW YORK, Aug. 21 /PRNewswire/ — ADHD is the most studied childhood psychiatric disorder and it can have a profound impact on children and their families. Because of the severity and pervasiveness of the symptoms, ADHD can cause problems academically, socially and psychologically, affecting a child’s self-esteem and ability to reach his/her full potential.
Today, Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has granted marketing clearance for Ritalin(R) LA (methylphenidate HCl) extended-release capsules, a new once-daily formulation of Ritalin(R) (methylphenidate HCl) that eliminates the need for a mid-day dose during school. The “LA” stands for long acting”, which means that the medication only needs to be taken once in the morning.
This video news release profiles a child who is being treated for ADHD and features an interview with a Harvard psychiatrist and animation of how medicine for ADHD works.
